VSIR and breast carcinoma: The first study to examine VISTA expression in the mammary tumor microenvironment revealed that immune cells expressing high levels of this protein positively correlate with prolonged relapse-free survival (RFS) and overall survival (OS), predicting a better prognosis for breast cancer patients (41).